MetaCap

Organogenesis Holdings Inc. Class A (ORGO)

NASDAQ: ORGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.7716-0.0176 (-2.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ORGO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$100.16M
EPS (TTM)
-$1.20
52-week range
0.73 – 5.91
Day range
0.7507 – 0.8163
Volume / Avg
792.59K / 850.26K
Beta
—

52-week range

$0.73$5.91

ORGO stock today

Shares of Organogenesis (ORGO) finished lower on Nov 20 at $0.7716, a drop of 2.23% or $0.0176 per share, versus the S&P 500's 3.70% decline. Shares are 86.9% below their 52-week high of $5.91, set on Dec 24, 2025 and 5.7% above the 52-week low of $0.73, near the bottom of the past year's range. ORGO is down 85.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 86.2%.

Organogenesis has posted a net loss over the last twelve months (EPS of -$1.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Organogenesis

Company profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Gary S. Gillheeney Sr.
Headquarters
Canton, MA
Employees
854
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Organogenesis generated $564.2 million in revenue, up 17.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $37.0 million (+4201.0% year over year), for a net margin of 6.6% versus a median of 3.4% in the prior 5 years. Operating margin was 7.9%.

Organogenesis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$564.17M$482.04M$433.14M$450.89M$467.36M
Growth+17.04%+11.29%-3.94%-3.52%+38.15%
Net income$37.03M$861.00K$4.95M$15.53M$94.20M
EPS (diluted)$0.15$-0.01$0.04$0.12$0.70

Analyst forecast

Forecast

Consensus (2 analysts)

hold

  • Strong buy 0
  • Buy 0
  • Hold 2
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.25 vs —

ORGO news

All ORGO news

Organogenesis peers

Health Care sector
ORGO peer companies
CompanyPrice% ChgMarket capCompare
NERVMinerva Neurosciences Inc2.00-5.66%$99.67Mvs ORGO
CNTNCanton Strategic Holdings Inc.1.21-1.63%$98.78Mvs ORGO
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs ORGO
FHTXFoghorn Therapeutics Inc.1.72-3.37%$103.14Mvs ORGO
GNLXGenelux Corporation2.17-4.82%$103.36Mvs ORGO
NBPNovaBridge Biosciences ADR0.83-5.66%$96.28Mvs ORGO
PDSBPDS Biotechnology Corporation0.7774-3.70%$95.39Mvs ORGO
NRXPNRX Pharmaceuticals Inc.2.15-15.69%$95.31Mvs ORGO

Indexes, lists and sector

Organogenesis stock FAQ

What is Organogenesis's stock price today?

ORGO last traded at $0.7716 as of Nov 20, 4:00 PM EST, down 2.23% on the day. Prices are delayed at least 15 minutes.

Who is Organogenesis's CEO?

Mr. Gary S. Gillheeney Sr. is the chief executive officer of Organogenesis Holdings Inc. Class A, which has about 854 employees.

What is the ORGO 52-week high?

The 52-week high for ORGO is $5.91 and the 52-week low is $0.73. The stock is currently 86.9% below its high.

Compare ORGO